Postinflammatory hyperpigmentation - Iwọn Hyperpigmentation Ti Postinflammatory
Iwọn Hyperpigmentation Ti Postinflammatory (Postinflammatory hyperpigmentation) jẹ ipo awọ-ara ti o jẹ ifihan nipasẹ pigmenti ti o pọ si ninu awọ ara lẹhin igbona awọ ara. iwọn hyperpigmentation ti postinflammatory (postinflammatory hyperpigmentation) le ṣẹlẹ nipasẹ isunmọ oorun gigun, iredodo, tabi awọn ipalara awọ ara miiran, pẹlu awọn ti o ni ibatan si irorẹ. Awọn eniyan ti o ni awọn ohun orin awọ dudu jẹ igbagbogbo diẹ sii si hyperpigmentation pẹlu ifihan oorun pupọ.
☆ Ninu awọn abajade 2022 Stiftung Warentest lati Jẹmánì, itẹlọrun alabara pẹlu ModelDerm jẹ kekere diẹ ju pẹlu awọn ijumọsọrọ telemedicine isanwo.
References
Postinflammatory hyperpigmentation (PIH) jẹ iṣoro awọ ara loorekoore ti o ṣẹlẹ lẹhin iredodo awọ tabi ipalara. O duro lati ṣiṣe ni igba pipẹ ati pe o buru julọ ni awọn eniyan ti o ni awọn awọ dudu dudu (Fitzpatrick skin types III–VI) . Botilẹjẹpe o nigbagbogbo dara si ara rẹ, eyi le gba igba diẹ, nitorinaa a nilo itọju nigbagbogbo fun igba pipẹ. Apapọ awọn itọju oriṣiriṣi ṣiṣẹ dara julọ.
Postinflammatory hyperpigmentation (PIH) is a common acquired cutaneous disorder occurring after skin inflammation or injury. It is chronic and is more common and severe in darker-skinned individuals (Fitzpatrick skin types III–VI). While the condition typically improves spontaneously, this process can take months to years, necessitating prolonged treatment. Combination therapy is the most effective.
Postinflammatory hyperpigmentation (PIH) is a common acquired cutaneous disorder occurring after skin inflammation or injury. It is chronic and is more common and severe in darker-skinned individuals (Fitzpatrick skin types III–VI). While the condition typically improves spontaneously, this process can take months to years, necessitating prolonged treatment. Combination therapy is the most effective.
Postinflammatory hyperpigmentation jẹ atẹle ti o wọpọ ti iredodo awọ ara. O duro lati ni ipa lori awọn eniyan dudu-awọ diẹ sii ni lile ati nigbagbogbo. Awọn ijinlẹ fihan pe awọn ọran bii postinflammatory hyperpigmentation wa laarin awọn idi akọkọ ti awọn eniyan ti o ni awọn awọ dudu dudu n wa itọju ti ara. Itọju tete jẹ pataki fun ipinnu postinflammatory hyperpigmentation ati nigbagbogbo bẹrẹ pẹlu iṣakoso ipo iredodo akọkọ. Laini akọkọ ti itọju ni igbagbogbo pẹlu lilo awọn aṣoju agbegbe ti o tan awọ ara pẹlu iboju oorun fun aabo. Awọn aṣoju wọnyi, bii hydroquinone, azelaic acid, kojic acid, arbutin, licorice extracts , le ni imunadoko lati dinku pigmenti pupọ. Ni afikun, retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, soy ni a tun lo bi awọn aṣoju ti o ni awọ-awọ, pẹlu awọn itọju titun ti n jade. Lakoko ti awọn itọju agbegbe maa n munadoko fun hyperpigmentation ipele-dada, awọn ilana (laser, chemical peel) le jẹ pataki fun awọn ọran alagidi. O ṣe pataki lati lo iṣọra pẹlu awọn itọju wọnyi lati yago fun ibinu ati buru si postinflammatory hyperpigmentation.
Postinflammatory hyperpigmentation is a common sequelae of inflammatory dermatoses that tends to affect darker skinned patients with greater frequency and severity. Epidemiological studies show that dyschromias, including postinflammatory hyperpigmentation, are among the most common reasons darker racial/ethnic groups seek the care of a dermatologist. The treatment of postinflammatory hyperpigmentation should be started early to help hasten its resolution and begins with management of the initial inflammatory condition. First-line therapy typically consists of topical depigmenting agents in addition to photoprotection including a sunscreen. Topical tyrosinase inhibitors, such as hydroquinone, azelaic acid, kojic acid, arbutin, and certain licorice extracts, can effectively lighten areas of hypermelanosis. Other depigmenting agents include retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, and soy with a number of emerging therapies on the horizon. Topical therapy is typically effective for epidermal postinflammatory hyperpigmentation; however, certain procedures, such as chemical peeling and laser therapy, may help treat recalcitrant hyperpigmentation. It is also important to use caution with all of the above treatments to prevent irritation and worsening of postinflammatory hyperpigmentation.
Postinflammatory hyperpigmentation is a common sequelae of inflammatory dermatoses that tends to affect darker skinned patients with greater frequency and severity. Epidemiological studies show that dyschromias, including postinflammatory hyperpigmentation, are among the most common reasons darker racial/ethnic groups seek the care of a dermatologist. The treatment of postinflammatory hyperpigmentation should be started early to help hasten its resolution and begins with management of the initial inflammatory condition. First-line therapy typically consists of topical depigmenting agents in addition to photoprotection including a sunscreen. Topical tyrosinase inhibitors, such as hydroquinone, azelaic acid, kojic acid, arbutin, and certain licorice extracts, can effectively lighten areas of hypermelanosis. Other depigmenting agents include retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, and soy with a number of emerging therapies on the horizon. Topical therapy is typically effective for epidermal postinflammatory hyperpigmentation; however, certain procedures, such as chemical peeling and laser therapy, may help treat recalcitrant hyperpigmentation. It is also important to use caution with all of the above treatments to prevent irritation and worsening of postinflammatory hyperpigmentation.
